Editing VEGFR1

{{DISPLAYTITLE:VEGFR1}}

'''VEGFR1''' (Vascular Endothelial Growth Factor Receptor 1), also known as '''Flt-1''' (Fms-like tyrosine kinase 1), is a protein that in humans is encoded by the '''FLT1''' gene. VEGFR1 is a member of the vascular endothelial growth factor receptor (VEGFR) family, which plays a crucial role in angiogenesis, the process of new blood vessel formation from pre-existing vessels.

==Structure==
VEGFR1 is a receptor tyrosine kinase (RTK) that consists of an extracellular domain, a single transmembrane helix, and an intracellular tyrosine kinase domain. The extracellular domain contains seven immunoglobulin-like loops that are responsible for binding to its ligands, primarily [[VEGF-A]], [[VEGF-B]], and [[PlGF]] (placental growth factor).

==Function==
VEGFR1 is involved in the regulation of angiogenesis and vasculogenesis. It acts as a decoy receptor for VEGF-A, sequestering it and preventing it from binding to [[VEGFR2]], which is the primary mediator of VEGF-induced angiogenic signaling. Despite its role as a decoy receptor, VEGFR1 also has signaling capabilities that can influence cell migration, survival, and differentiation.

===Ligand Binding===
VEGFR1 binds to VEGF-A with high affinity, but its kinase activity is weaker compared to VEGFR2. The binding of VEGF-B and PlGF to VEGFR1 can modulate the availability of VEGF-A for VEGFR2, thus indirectly influencing angiogenic signaling.

===Signaling Pathways===
Upon ligand binding, VEGFR1 undergoes dimerization and autophosphorylation, activating downstream signaling pathways. These pathways include the [[PI3K/AKT pathway]], which is involved in cell survival, and the [[MAPK/ERK pathway]], which is associated with cell proliferation and migration.

==Clinical Significance==
VEGFR1 is implicated in various pathological conditions, including cancer, where it can contribute to tumor angiogenesis and metastasis. It is also involved in inflammatory diseases and ocular disorders such as age-related macular degeneration (AMD).

===Therapeutic Target===
VEGFR1 is a target for anti-angiogenic therapies. Inhibitors of VEGFR1, such as monoclonal antibodies and small molecule tyrosine kinase inhibitors, are being developed to treat cancers and other diseases characterized by excessive angiogenesis.

==Research and Development==
Ongoing research is focused on understanding the precise role of VEGFR1 in different tissues and its potential as a biomarker for disease progression and treatment response. Studies are also exploring the development of selective VEGFR1 inhibitors that can provide therapeutic benefits with minimal side effects.

==Also see==
* [[VEGFR2]]
* [[VEGF-A]]
* [[Angiogenesis]]
* [[Receptor tyrosine kinase]]
* [[Cancer therapy]]

{{Receptor tyrosine kinases}}
{{Angiogenesis}}

[[Category:Receptor tyrosine kinases]]
[[Category:Angiogenesis]]
[[Category:Oncology]]
__NOINDEX__
{{No image}}
__NOINDEX__